Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Consensus "Buy": Ten brokerages cover Rapport Therapeutics with a consensus rating of Buy (1 sell, 7 buy, 2 strong buys) and an average 12‑month price target of $54.83.
• Recent results and stock metrics: the company reported a Q1 EPS miss (‑$0.72 vs. ‑$0.65 est.), the stock opened at $33.74 (down ~4.7%), market cap ~$1.61B, negative PE, and analysts forecast ~‑$3.01 EPS for the year.
• Insider selling: insiders have sold 487,885 shares (~$19.3M) in the last 90 days — including a 426,005‑share sale by Rock Ventures — though insiders still hold 13.57% of shares outstanding.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) has been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $54.8333.

Several brokerages have commented on RAPP. BTIG Research reaffirmed a "buy" rating and set a $53.00 target price on shares of Rapport Therapeutics in a report on Wednesday, April 22nd. Wall Street Zen downgraded Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Truist Financial upgraded Rapport Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. Raymond James Financial assumed coverage on Rapport Therapeutics in a research report on Friday, April 10th. They set a "strong-buy" rating and a $66.00 price objective for the company. Finally, Citigroup restated a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th.

Rapport Therapeutics Trading Down 4.7%

Rapport Therapeutics stock opened at $33.74 on Wednesday. The company has a market capitalization of $1.61 billion, a PE ratio of -11.80 and a beta of 1.09. Rapport Therapeutics has a 12 month low of $7.73 and a 12 month high of $42.27. The stock has a 50-day moving average price of $31.46 and a two-hundred day moving average price of $29.00.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.07). As a group, analysts predict that Rapport Therapeutics will post -3.01 earnings per share for the current fiscal year.

Insider Activity at Rapport Therapeutics

In other news, COO Cheryl Gault sold 2,014 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $28.93, for a total transaction of $58,265.02. Following the completion of the transaction, the chief operating officer directly owned 169,914 shares in the company, valued at $4,915,612.02. This trade represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Rock Ventures V. L.P. Third sold 426,005 shares of the firm's stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $40.32, for a total value of $17,176,521.60. Following the transaction, the insider owned 6,709,228 shares of the company's stock, valued at $270,516,072.96. This trade represents a 5.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 487,885 shares of company stock valued at $19,319,002 over the last ninety days. Insiders own 13.57% of the company's stock.

Hedge Funds Weigh In On Rapport Therapeutics

A number of hedge funds have recently made changes to their positions in RAPP. Meeder Asset Management Inc. bought a new position in shares of Rapport Therapeutics during the fourth quarter worth about $37,000. Russell Investments Group Ltd. bought a new position in shares of Rapport Therapeutics during the third quarter worth about $43,000. Strs Ohio raised its position in shares of Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company's stock worth $62,000 after acquiring an additional 400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Rapport Therapeutics by 64.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock worth $70,000 after acquiring an additional 905 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock worth $99,000 after acquiring an additional 4,582 shares during the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.